Zentalis Pharmaceuticals logo

Zentalis PharmaceuticalsNASDAQ: ZNTL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 April 2020

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$242.30 M
-93%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-93%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 21:32:27 GMT
$3.40-$0.60(-15.00%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

ZNTL Latest News

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
gurufocus.com07 October 2024 Sentiment: POSITIVE

FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LLC (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares.

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
zacks.com17 September 2024 Sentiment: POSITIVE

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
prnewswire.com16 September 2024 Sentiment: NEGATIVE

NEW YORK , Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) breached their fiduciary duties to shareholders.

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
benzinga.com16 September 2024 Sentiment: POSITIVE

Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1.

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
globenewswire.com16 September 2024 Sentiment: POSITIVE

Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024

Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
zacks.com26 August 2024 Sentiment: NEGATIVE

The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Clients to Contact the Firm!
accesswire.com18 August 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm
accesswire.com17 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm
accesswire.com15 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ZNTL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm Today!
accesswire.com15 August 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZNTL.

What type of business is Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

What sector is Zentalis Pharmaceuticals in?

Zentalis Pharmaceuticals is in the Healthcare sector

What industry is Zentalis Pharmaceuticals in?

Zentalis Pharmaceuticals is in the Biotechnology industry

What country is Zentalis Pharmaceuticals from?

Zentalis Pharmaceuticals is headquartered in United States

When did Zentalis Pharmaceuticals go public?

Zentalis Pharmaceuticals initial public offering (IPO) was on 03 April 2020

What is Zentalis Pharmaceuticals website?

https://zentalis.com

Is Zentalis Pharmaceuticals in the S&P 500?

No, Zentalis Pharmaceuticals is not included in the S&P 500 index

Is Zentalis Pharmaceuticals in the NASDAQ 100?

No, Zentalis Pharmaceuticals is not included in the NASDAQ 100 index

Is Zentalis Pharmaceuticals in the Dow Jones?

No, Zentalis Pharmaceuticals is not included in the Dow Jones index

When was Zentalis Pharmaceuticals the previous earnings report?

No data

When does Zentalis Pharmaceuticals earnings report?

The next expected earnings date for Zentalis Pharmaceuticals is 27 February 2025